Innovating Works

GSKBIO

Desconocido
Showing 1 to 20 of 32 results
PrIMAVeRa: Predicting the Impact of Monoclonal Antibodies Vaccines on Antimicrobial Resistance GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2020-23-two-stage Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-speci...
2021-11-09 - 2026-10-31 | Financiado
Inno4Vac: Innovations to accelerate vaccine development and manufacture GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado
PROMISE: Preparing for RSV Immunisation and Surveillance in Europe GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado
Vacc-iNTS: Advancing a GMMA based vaccine against invasive non typhoidal salmonellosis through Phase 1 trial in... Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan A...
2019-04-30 - 2026-07-31 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado
DRIVE: Development of Robust and Innovative Vaccine Effectiveness GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2016-09-two-stage Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the...
2017-08-08 - 2022-06-30 | Financiado
RESCEU: REspiratory Syncytial virus Consortium in EUrope Sofia ref. 116019 GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2015-06-two-stage RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk gr...
2016-12-14 - 2022-09-30 | Financiado
PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado
VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado
DiViNe: Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies novel a... GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-BIOTEC-2014-2015 In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any cont...
2015-02-11 - 2020-02-29 | Financiado
EbolaVac: Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine GLAXOSMITHKLINE BIOLOGICALS SA tramitó un H2020 DIGITAL-2024-CLOUD-AI-06 The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organizatio...
2014-12-09 - 2018-04-06 | Financiado
TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020 H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6 Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado
ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6 Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado
BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6 BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado
ADJSYN: Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7 The need to develop vaccines against challenging diseases such as malaria or tuberculosis requires effective adjuvants to improve the immune...
Financiado
SIMULATA: System for Immunological Modelling as an Ultimate tool to Link Adjuvant function To Adaptive immune... GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7 The aim of the proposal is to construct an in vitro model of human cellular immune responses and to address fundamental questions on the lin...
Financiado
T-BAC: Exploring the roles and plasticity of T cell responses in anti BACterial immunity GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7 "Antibodies against bacterial polysaccharides and proteins play a role in anti-bacterial immunity. To date, S. aureus vaccine candidates wer...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.